AEMD : Summary for Aethlon Medical, Inc. - Yahoo Finance

U.S. Markets closed

Aethlon Medical, Inc. (AEMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.27+0.07 (+3.18%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.20
Bid2.00 x 1500
Ask2.28 x 2400
Day's Range2.13 - 2.28
52 Week Range2.13 - 9.09
Avg. Volume41,085
Market Cap19.97M
PE Ratio (TTM)-2.57
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire19 days ago

    Aethlon Medical Discloses Tech Nation Interview On National Public Radio

    SAN DIEGO, April 4, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, disclosed today that an interview conducted with Company CEO Jim Joyce on the weekly Tech Nation radio program is available to be accessed online at  The 27 minute interview begins at minute six of the program and ends at minute 33. Tech Nation is a weekly public radio program, hosted by Dr. Moira Gunn. Founded in 1993, the program features conversations with noted technology and science leaders, and a weekly science and technology-related commentary.  In the U.S., Tech Nation, and its regular segment BioTech Nation, can be heard multiple times each week on the NPR Channel of SiriusXM Satellite Radio and SiriusXM Internet Radio.

  • PR Newswirelast month

    Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study

    SAN DIEGO, March 13, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the company has concluded an FDA-approved feasibility study designed to assess the safety of the Aethlon Hemopurifier® in health-compromised individuals. The Hemopurifier is a first-in-class medical device that reduces the presence of circulating viruses in infected individuals. The technology is a first-line candidate defense against a broad-spectrum of viruses that are not addressed with antiviral drug therapies, including natural occurring pandemic threats and agents of bioterrorism.  Additionally, the device provides a strategy to augment the benefit of proven antiviral drug regimens.

  • PR Newswire2 months ago

    Aethlon Medical To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 14, 2017

    SAN DIEGO, March 8, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 29th Annual Growth Stock ...